GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial

GlycoMimetics GLYC announced late Friday afternoon that Pfizer's PFE Phase 3 clinical trial evaluating Rivipansel in sickle cell disease has not met its primary or key secondary endpoints.

On Monday morning, a number of firms have downgraded the stock:

  • Jefferies downgraded the stock from Buy to Hold.
  • SunTrust Robinson Humphrey downgraded from Buy to Hold and lowered the price target from $23 to $5.
  • Piper Jaffray downgraded from Overweight to Neutral and lowered the price target from $20 to $6.

GlycoMimetics shares were trading down 51.81% at $4.40 in Monday’s pre-market session. The stock has a 52-week high of $17.07 and a 52-week low of $8.29.

Related Links:

The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA

Posted In: NewsHealth CareTop StoriesMoversTrading IdeasGeneralRivipanselsickle cellSickle Cell Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...